PHIBRO ANIMAL HEALTH CORP PAHC

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. We market approximately 790 product lines in approximately 90 countries to approximately 4,800 customers. We develop, manufacture and market a broad range of products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. Our products help prevent, control and treat diseases and support nutrition to help improve animal health and well-being. We sell animal health and mineral nutrition products either directly to integrated poultry, cattle and swine producers or through animal feed manufacturers, wholesalers, distributors and veterinarians.

Last close 38.80 2026-10-23
Market cap $1.57B estimated share count
52-week range 28.25 - 60.08

Valuation FY2026 figures against the last close

P/S1.0x
P/E16.0x
P/FCF159.5x
EV/EBITDA6.4x
Dividend yield1.2%
Diluted EPS2.43

Where the revenue comes from as reported in the latest 10-K

Revenue by segment

  • Animal Health
  • Mineral Nutrition
  • Performance Products
Revenue by segment, 3 categories over 3 years. The same figures are in the table below. FY2026 Animal Health, FY2026: 1.2B (76.6%) 77% Animal Health Mineral Nutrition, FY2026: 282.3M (18.6%) 19% Mineral Nutrition Performance Products, FY2026: 73.5M (4.8%) 5% FY2025 Animal Health, FY2025: 962.8M (74.3%) 74% Mineral Nutrition, FY2025: 253.2M (19.5%) 20% Performance Products, FY2025: 80.2M (6.2%) 6% FY2024 Animal Health, FY2024: 706.5M (69.4%) 69% Mineral Nutrition, FY2024: 243.7M (23.9%) 24% Performance Products, FY2024: 67.5M (6.6%) 7%
Segment FY2026FY2025FY2024
Animal Health $1.16B $962.8M $706.5M
Mineral Nutrition $282.3M $253.2M $243.7M
Performance Products $73.5M $80.2M $67.5M

As the company reported it, from the “Business Segments - Net Sales (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $1.52B$1.30B$1.02B$977.9M$942.3M$833.4M$800.4M$828.0M$820.0M$764.3M
Cost of revenue $1.01B$896.3M$704.6M$679.7M$656.9M$562.0M$543.5M$563.4M$553.1M$516.0M
Gross profit $512.5M$399.9M$313.1M$298.2M$285.4M$271.4M$256.9M$264.6M$266.9M$248.2M
R&D $24.6M$23.7M$29.2M$24.4M$20.8M$17.8M$13.7M$12.1M$10.0M$9.4M
SG&A $318.1M$289.5M$259.8M$226.4M$206.4M$196.5M$187.7M$181.4M$168.0M$150.3M
Operating income $194.4M$110.5M$53.3M$71.8M$79.0M$74.9M$69.2M$83.2M$98.9M$97.9M
Interest expense $46.4M$37.2M$23.0M$18.7M$12.7M$13.7M$14.6M$13.7M$13.6M$14.9M
Pre-tax income $137.3M$68.0M$10.9M$54.1M$72.3M$66.5M$55.5M$71.5M$88.1M$80.5M
Income tax $37.6M$19.7M$8.5M$21.5M$23.2M$12.1M$22.0M$16.8M$23.2M$15.9M
Net income $99.7M$48.3M$2.4M$32.6M$49.2M$54.4M$33.6M$54.7M$64.9M$64.6M
EPS, basic 2.461.190.060.811.211.340.831.351.611.63
EPS, diluted 2.431.190.060.811.211.340.831.351.611.61
Shares, diluted (wtd. avg.) 41.0M40.7M40.5M40.5M40.5M40.5M40.5M40,52340,38540,042

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $61.4M$68.0M$70.6M$41.3M$74.2M$50.2M$36.3M$57.6M$29.2M$56.1M
Short-term investments $20.6M$9.0M$44.0M$40.0M$17.0M$43.0M$55.0M$24.0M$50.0M—
Receivables $238.8M$228.0M$169.5M$163.5M$166.5M$146.9M$126.5M$159.0M$135.7M$125.8M
Inventory $534.9M$444.4M$265.9M$277.6M$259.2M$216.3M$196.7M$198.3M$178.2M$161.2M
Total current assets $935.5M$810.6M$601.0M$585.7M$566.2M$498.9M$451.8M$466.2M$415.5M$363.7M
Property, plant and equipment $369.2M$354.7M$203.3M$195.6M$165.5M$154.7M$148.1M$140.2M$130.1M$127.4M
Goodwill $60.0M$59.6M$54.6M$53.3M$53.2M$52.7M$52.7M$27.3M$27.3M$24.0M
Other intangibles $30.1M$36.5M$45.0M$55.0M$63.9M$62.3M$71.0M$47.5M$52.0M$54.6M
Total assets $1.50B$1.36B$982.2M$971.4M$931.7M$841.3M$784.1M$726.7M$671.7M$623.4M
Accounts payable $127.3M$138.2M$85.6M$73.9M$95.6M$68.4M$66.1M$73.2M$59.5M$56.9M
Short-term debt ——$29.8M$22.3M$15.0M————$6.2M
Total current liabilities $316.5M$293.5M$204.1M$176.0M$190.8M$164.1M$157.2M$154.2M$143.2M$115.8M
Long-term debt ——$282.3M$311.5M$272.9M—————
Total liabilities $1.12B$1.08B$725.5M$688.9M$669.3M$602.8M$595.9M$510.7M$486.7M$472.2M
Retained earnings $353.0M$272.7M$243.9M$260.9M$247.7M$218.0M$183.1M$168.9M$131.6M$82.8M
Total equity $385.5M$285.7M$256.6M$282.5M$262.4M$238.5M$188.2M$216.0M$185.0M$151.2M

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $69.0M$80.1M$87.6M$13.3M$31.6M$48.3M$59.3M$47.2M$70.0M$98.4M
Depreciation and amortisation $51.5M$45.6M$36.2M$34.0M$32.7M$31.9M$32.3M$27.6M$26.9M$26.0M
Stock-based compensation $1.6M$717.0K$475.0K——$1.1M$2.3M$2.3M$334.0K$0
Capital expenditure $59.1M$38.3M$41.2M$51.8M$37.0M$29.3M$34.0M$29.9M$18.5M$20.9M
Investing cash flow -$71.5M-$288.7M-$48.2M-$74.0M-$22.6M-$18.6M-$120.4M-$14.1M-$84.6M-$21.9M
Financing cash flow -$6.6M$207.1M-$6.8M$27.0M$16.3M-$17.0M$40.9M-$4.1M-$11.8M-$53.7M
Dividends paid $19.5M$19.4M$19.4M$19.4M$19.4M$19.4M$19.4M$18.6M$16.1M$15.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-101493.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 500M 1B 1.5B 2B Revenue, FY2017: 764.3M Gross profit, FY2017: 248.2M Net income, FY2017: 64.6M Revenue, FY2018: 820M Gross profit, FY2018: 266.9M Net income, FY2018: 64.9M Revenue, FY2019: 828M Gross profit, FY2019: 264.6M Net income, FY2019: 54.7M Revenue, FY2020: 800.4M Gross profit, FY2020: 256.9M Net income, FY2020: 33.6M Revenue, FY2021: 833.4M Gross profit, FY2021: 271.4M Net income, FY2021: 54.4M Revenue, FY2022: 942.3M Gross profit, FY2022: 285.4M Net income, FY2022: 49.2M Revenue, FY2023: 977.9M Gross profit, FY2023: 298.2M Net income, FY2023: 32.6M Revenue, FY2024: 1B Gross profit, FY2024: 313.1M Net income, FY2024: 2.4M Revenue, FY2025: 1.3B Gross profit, FY2025: 399.9M Net income, FY2025: 48.3M Revenue, FY2026: 1.5B Gross profit, FY2026: 512.5M Net income, FY2026: 99.7M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue $764.3M $820.0M $828.0M $800.4M $833.4M $942.3M $977.9M $1.02B $1.30B $1.52B
Gross profit $248.2M $266.9M $264.6M $256.9M $271.4M $285.4M $298.2M $313.1M $399.9M $512.5M
Net income $64.6M $64.9M $54.7M $33.6M $54.4M $49.2M $32.6M $2.4M $48.3M $99.7M

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Other event Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%